Microbot Medical Inc. (NASDAQ:MBOT) Stock Rated "Hold" by Wall Street Analysts

Key Points

• Microbot Medical holds an average “Hold” rating from five analysts: three “Buy,” one “Hold,” and one “Sell.” The average 12-month price target is $6.38.
• MBOT shares opened at $0.95, near their 12-month low of $0.93 and well below the $2.89 high; the stock has a market capitalization of approximately $63.81 million.
• Institutional investors own 16.30% of the company, while the latest quarterly results showed an adjusted loss of $0.08 per share and revenue of $0.24 million, exceeding the $0.13 million consensus estimate.

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) has earned an average rating of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $6.38.

A number of research analysts have issued reports on MBOT shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Microbot Medical in a research note on Friday, October 2nd. B. Riley Financial assumed coverage on Microbot Medical in a research report on Friday, September 11th. They set a "buy" rating and a $4.00 price target on the stock. Zacks Research lowered Microbot Medical from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 20th. HC Wainwright restated a "buy" rating on shares of Microbot Medical in a report on Wednesday, August 19th. Finally, Wall Street Zen raised shares of Microbot Medical from a "strong sell" rating to a "sell" rating in a research note on Saturday, September 19th.

Institutional Trading of Microbot Medical

Several hedge funds and other institutional investors have recently modified their holdings of MBOT. CTC Alternative Strategies Ltd. bought a new stake in shares of Microbot Medical in the first quarter valued at about $28,000. Cetera Investment Advisers boosted its position in shares of Microbot Medical by 44.7% during the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company's stock worth $102,000 after buying an additional 13,099 shares during the period. Private Advisor Group LLC acquired a new position in shares of Microbot Medical during the first quarter worth about $54,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Microbot Medical during the fourth quarter worth about $65,000. Finally, Bank of America Corp DE grew its holdings in shares of Microbot Medical by 1,688.1% during the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company's stock worth $183,000 after buying an additional 71,560 shares in the last quarter. Institutional investors and hedge funds own 16.30% of the company's stock.

Microbot Medical Price Performance

Shares of NASDAQ MBOT opened at $0.95 on Friday. Microbot Medical has a twelve month low of $0.93 and a twelve month high of $2.89. The stock has a market cap of $63.81 million, a price-to-earnings ratio of -3.96 and a beta of 1.05. The company's fifty day moving average is $1.37 and its 200-day moving average is $1.76.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, meeting analysts' consensus estimates of ($0.08). The firm had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. On average, research analysts anticipate that Microbot Medical will post -0.30 EPS for the current fiscal year.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.

Microbot Medical's primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.